CA125 guided strategy

DRUG2 trials

Sponsors

Fundación para la Investigación del Hospital Clínico de Valencia

Conditions

Heart Failure

Phase 4

Carbohydrate Antigen 125-guided Therapy in Heart Failure

CompletedNCT02008110

Fundación para la Investigación del Hospital Clínico de ValenciaHeart Failure

Start: 2011-12-31End: 2015-05-31Updated: 2016-02-04

Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF)

CompletedNCT02643147

Fundación para la Investigación del Hospital Clínico de ValenciaHeart Failure

Start: 2015-01-31End: 2017-01-30Updated: 2018-02-13

Related Papers

Implication of stereotactic body radiotherapy (SBRT) as a neoadjuvant treatment in hepatobiliary malignancies – A single centre experience

International Journal of Surgery2022-04-01

Early urinary sodium trajectory and risk of adverse outcomes in acute heart failure and renal dysfunction.

2020-07-025 citations

Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study.

2016-08-1094 citations

Prognostic effect of carbohydrate antigen 125-guided therapy in patients recently discharged for acute heart failure (CHANCE-HF). Study design.

2014-08-102 citations